Biotechnology

MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025

SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...

2025-04-08 15:38 2719

Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer

* This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development. * The partnership will advance the development of first-in-class precision therapeutics for multiple cancer ty...

2025-04-08 09:00 2574

AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company

HONG KONG, April 8, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced onApril 7, 2025 that the company's research and development of the serum-free iterative rabies vaccine has received an "Acceptance Notice" from the National Medical Products Admini...

2025-04-08 08:00 2369

World Health Day Focus: Yeast Protein for Muscle Gain Unveiled through Scientific Clinical Trials

YICHANG, China, April 7, 2025 /PRNewswire/ -- In recognition of World Health Day 2025, themed "Healthy Beginnings, Hopeful Futures," Angel Yeast (SH600298), an innovation-driven global biotechnology brand, is championing inclusive health solutions that transcend g...

2025-04-07 16:41 3346

Duality Bio Appoints Hua Mu as Global Chief Medical Officer

SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient execution, and comprehensive regulatory compliance of the company...

2025-04-07 12:52 2441

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectivelydeliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and n...

2025-04-07 08:34 4493

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company's growth and vision to help bring certainty and transparency to global clinical trials SINGAPORE, April 7, 2025 /PRNewswire/ -- George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to becomeEmerald ...

2025-04-07 08:00 2504

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr.Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.   Dr. Schaffer has...

2025-04-07 07:09 3875

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journalNature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for th...

2025-04-06 10:12 3337

Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition

Jasmine Eyal, Age 16, of Singapore, Receives Top Honors and $400,000 in Education Prizes for her Original Video Explaining Mechanogenetic Cellular Engineering LOS ANGELES, April 6, 2025 /PRNewswire/ -- The Breakthrough Prize Foundation today announcedSingapore-based Jasmine Eyal as winner of the...

2025-04-06 06:30 3274

BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS

"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA Editing Exploration of Nature at Shortest Distances  Proof of Geometric Langlands Conjecture Special Prize Awarded to Giant of Theoretical Physics Breakthrou...

2025-04-06 06:30 2614

I Peace Launches Personalized iPS Cell Services and Longevity Treatment in the U.S.

– Age-Reversed Stem Cell Technology Now Available to the Public – PALO ALTO, Calif., April 5, 2025 /PRNewswire/ -- I Peace, Inc. ( https://ipeace.com/en/ ), a global pioneer in iPSC (induced pluripotent stem cell) technology, proudly announces the launch of its personalize...

2025-04-05 20:00 2944

Ex-FDA Expert Dr. Yaning Wang Joins Tsingke to Drive Small Nucleic Acid Drug Innovation

BEIJING, April 4, 2025 /PRNewswire/ -- Recently, Beijing Tsingke Biotech Co., Ltd. officially announced the appointment of Dr.Yaning Wang, a former senior expert at the FDA, as the company's Chief Scientific Advisor in the field of small nucleic ac...

2025-04-04 20:58 4456

OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate Glioblastoma Therapies

SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies, today announced that it has entered into a Common Stock Purchase Agreement with White Lion GBM Innovation Fund ("Innovation Fund")...

2025-04-03 19:30 6297

Fangzhou Designated as a 2024 National High-Tech Enterprise Amid Record Growth

BEIJING, April 3, 2025 /PRNewswire/ -- Beijing Fangyixing Information Technology Co., Ltd. ("Fangyixing"), a subsidiary ofChina's leading Internet healthcare solutions provider Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), has been certified as a 2024 National High-Tech Enterprise, sol...

2025-04-03 15:25 4080

IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery

De-Risking Target Validation with Data-Driven Genomic Insights ROME, April 3, 2025 /PRNewswire/ -- IRBM, an integrated Contract Research Organization (CRO) specializing in preclinical drug discovery, has established a comprehensive Functional Genomics Platform to support genetic target identific...

2025-04-03 07:45 4525

TCI Biotech Expands US Glass Bottling Capabilities for Liquid Nutraceuticals Innovation

TAIPEI, April 2, 2025 /PRNewswire/ -- TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling solution for liquid supplements, positioning it as a cornerstone of its expanded CDMO+ services. Designed...

2025-04-03 00:00 3312

Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor

SHANGHAI, April 2, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel B7-H3-targeting ADC (R&D code: 7MW3711) has been approved by the NMPA to enter Phase Ib/II clinical trial in combination with a PD-1 Inhibitor, with...

2025-04-02 22:00 3103

Change in Management: Exyte announces Katrien Verlinden as new President of its Global Business Unit Advanced Technology Facilities

* Katrien Verlinden will take over as President of Exyte's Global Business Unit Advanced Technology Facilities (ATF) effectiveApril 14, 2025 * Verlinden joins from Saipem America Inc., where she served as President and CEO, bringing more than 25 years of international leadership experience *...

2025-04-02 17:00 2781

Senhwa Biosciences Announces Positive Clinical Data from Phase 1/Expansion Trial of Silmitasertib (CX-4945) in the Treatment of Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights * CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. * Optimal Treatment Response: Three patients achieved partial response (PR), while ten patients had stable disease (SD). * Tolerability & Disease Control Rate: Sho...

2025-04-02 15:56 2607
1 ... 51525354555657 ... 342

Week's Top Stories